Daniel Y. Wang, MD

Articles by Daniel Y. Wang, MD

Immune Checkpoint Inhibitor Therapy in Patients With Autoimmune Disease

ByDouglas B. Johnson, MD, MSCI,Kathryn E. Beckermann, MD, PhD,Daniel Y. Wang, MD

April 15th 2018

In this article, we detail the experience with immune checkpoint inhibitors in patients with autoimmune disease.

Combination Immunotherapy: An Emerging Paradigm in Cancer Therapeutics

ByDaniel Y. Wang, MD,Jeffrey A. Sosman, MD,Douglas B. Johnson, MD, MSCI

December 15th 2015

In view of the potential for durable responses with immunotherapy, it will be important to identify the most effective and least toxic regimens for individual patients.

Latest Updated Articles

Combination Immunotherapy: An Emerging Paradigm in Cancer Therapeutics
Published: December 15th 2015 | Updated:
Immune Checkpoint Inhibitor Therapy in Patients With Autoimmune Disease
Published: April 15th 2018 | Updated:

Daniel Y. Wang, MD

Articles by Daniel Y. Wang, MD

Immune Checkpoint Inhibitor Therapy in Patients With Autoimmune Disease

Combination Immunotherapy: An Emerging Paradigm in Cancer Therapeutics

Latest Updated Articles

Trending on CancerNetwork

177Lu-PSMA-I&T/223Ra Display Safety and Feasibility in Metastatic CRPC

Novel Intratumoral Formulation Shows Responses/Safety in Metastatic Cancers

Radiotherapy Plus Chemoimmunotherapy Improves Frontline ES-SCLC Prognosis

Matched donor allogeneic CAR T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion

Durvalumab Plus Concurrent CRT Does Not Add Benefit in Stage III NSCLC